BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 142,958 Shares of Merck & Co., Inc. (NYSE:MRK)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,414,789 shares of the company's stock after selling 142,958 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.06% of Merck & Co., Inc. worth $160,663,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in MRK. China Universal Asset Management Co. Ltd. lifted its position in Merck & Co., Inc. by 16.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 63,101 shares of the company's stock valued at $7,211,000 after buying an additional 8,985 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Merck & Co., Inc. by 3.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,837,354 shares of the company's stock valued at $208,649,000 after purchasing an additional 62,047 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Merck & Co., Inc. by 30.2% during the third quarter. Crossmark Global Holdings Inc. now owns 246,414 shares of the company's stock valued at $27,983,000 after purchasing an additional 57,106 shares during the last quarter. AMF Tjanstepension AB boosted its position in shares of Merck & Co., Inc. by 114.2% in the 3rd quarter. AMF Tjanstepension AB now owns 802,384 shares of the company's stock worth $91,205,000 after purchasing an additional 427,831 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Merck & Co., Inc. by 5.3% in the 3rd quarter. Victory Capital Management Inc. now owns 2,973,364 shares of the company's stock worth $337,655,000 after buying an additional 150,873 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $97.43 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. Merck & Co., Inc. has a 12-month low of $94.48 and a 12-month high of $134.63. The firm has a market capitalization of $246.46 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.39 and a beta of 0.40. The firm has a 50 day moving average of $107.74 and a 200 day moving average of $118.24.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The company's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 7.73 earnings per share for the current year.

Merck & Co., Inc. Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 8th. Investors of record on Monday, December 16th will be issued a $0.81 dividend. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.77. The ex-dividend date is Monday, December 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.33%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 64.57%.

Wall Street Analyst Weigh In

Several research firms have commented on MRK. Bank of America dropped their target price on Merck & Co., Inc. from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Wolfe Research assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Guggenheim dropped their target price on shares of Merck & Co., Inc. from $137.00 to $130.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Finally, UBS Group reduced their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $130.86.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.